First Time Loading...

ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 67.11 USD 0.89%
Updated: May 3, 2024

ANI Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ANI Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Revenue
$486.8m
CAGR 3-Years
33%
CAGR 5-Years
19%
CAGR 10-Years
32%
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

ANI Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
ANI Pharmaceuticals Inc

Total Revenue: 486.8m USD
100%
United States: 486.3m USD
99.9%
Canada: 565k USD
0.1%

Breakdown by Segments
ANI Pharmaceuticals Inc

Total Revenue: 486.8m USD
100%
Sales Of Generic Pharmaceutical Products: 269.4m USD
55.3%
Sales Of Rare Disease Pharmaceutical Products: 112.1m USD
23%
Sales Of Established Brand Pharmaceutical Pro...: 105.3m USD
21.6%
Unapproved Products: 22.4m USD
4.6%
Show More
Show Less

See Also

What is ANI Pharmaceuticals Inc's Revenue?
Revenue
486.8m USD

Based on the financial report for Dec 31, 2023, ANI Pharmaceuticals Inc's Revenue amounts to 486.8m USD.

What is ANI Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
32%

Over the last year, the Revenue growth was 54%. The average annual Revenue growth rates for ANI Pharmaceuticals Inc have been 33% over the past three years , 19% over the past five years , and 32% over the past ten years .